How has Kura Oncology's accrued expenses and other liabilities changed year-over-year?

Kura Oncology's accrued expenses and other liabilities decreased by 88.3% year-over-year, from -$8.61M to -$16.22M.

Kura Oncology KURA Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Syndax PharmaceuticalsSNDX

——

Corvus PharmaceuticalsCRVS

——

Nuvalent, Inc.NUVL

——

Vertex PharmaceuticalsVRTX

——

Other financials

Income statement

See full

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

See full

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

See full

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

See full

Market cap$919.7M+81.6%

Enterprise value$904.89M+90.7%

P/S12.8×+3.5×

Profitability

See full

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

See full

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kura Oncology's accrued expenses and other liabilities?: Kura Oncology (KURA) reported accrued expenses and other liabilities of -$16.22M in Q1 2026.
How has Kura Oncology's accrued expenses and other liabilities changed year-over-year?: Kura Oncology's accrued expenses and other liabilities decreased by 88.3% year-over-year, from -$8.61M to -$16.22M.